Shots:

• The P-III TIDES study contains three parts assessing TAK-003 (0.5ml- SC) vs PBO in patients for the prevention of dengue fever of any severity and due to any of the four dengue virus serotypes in children and adolescents- evaluating the efficacy- safety and immunogenicity
• The P-III study demonstrated well-tolerated- safe and efficacious results in preventing fever till date and is being continued with expected results in H2’19
• Takeda’ TAK-003 is a tetravalent live-attenuated dengue serotype 2 virus and has shown safe and well-tolerated results in P-I/II study for children and adolescent

   Ref: Takeda| Image: Takeda